Sayana® Press: Pilot Introduction
The Uniject injection system was developed in the 1980s and has been used since the late 1990s. PATH has been working with the commercial producers of Depo-Provera and Uniject to develop the product for the past decade. Acceptability studies and operational assessments are taking place between 2009 and 2013. Product pilot introduction will take place between 2013 and 2016.
Acceptability studies and operational assessments are taking place in Senegal and Uganda. Locations for product pilot introduction will be determined in 2013.
The Sayana Press pilot introduction partnership includes the Bill & Melinda Gates Foundation, the US Agency for International Development (USAID), the United Kingdom’s Department for International Development (DFID), the United Nations Population Fund (UNFPA), Pfizer Inc., and PATH. Acceptability studies are being conducted in collaboration with FHI 360.
Bill & Melinda Gates Foundation and the US Agency for International Development.
Uniject is a trademark of BD. Depo-Provera, depo-subQ provera 104, and Sayana Press are trademarks of Pfizer.